What drove the intraday drop in IDIA.SW stock today?

The intraday fall to **CHF 2.84** came with a volume spike to **3,753,802** shares. Market selling pressure, below-average technicals and profit-taking after recent gains were drivers. No single public catalyst was confirmed at time of writing.

What is Meyka AI's 12-month forecast for IDIA.SW stock?

Meyka AI's forecast model projects a 12-month level near **CHF 5.60**, implying about **97.02%** upside versus the current **CHF 2.84**. Forecasts are model projections and not guarantees.

How does Idorsia's valuation compare to the healthcare sector?

Idorsia shows a price-to-sales of **3.08** and a current ratio of **1.39**, below the Swiss healthcare sector current ratio **1.91** and sector average PE **29.59**, indicating tighter liquidity and a different valuation profile versus larger drugmakers.

When is Idorsia's next earnings announcement?

Idorsia’s next earnings announcement is scheduled for **2026-04-28**. Traders should watch that release and any clinical trial updates for short-term price drivers.

CH Stocks

IDIA.SW Idorsia Ltd (SIX) drops to CHF 2.84 on 16 Mar 2026: signals trading interest

ByHuzaifa Zahoor March 16, 2026March 16, 2026

Intraday trading shows IDIA.SW stock at CHF 2.84, down 19.66% on 16 Mar 2026 as volume surged to 3,753,802 shares on the SIX exchange in Switzerland. That move follows a weak open at CHF 3.24 and pushes the name well below its 50-day average of CHF 3.76 and near the 200-day average of CHF 3.34. For most-active lists today, Idorsia Ltd’s drop combines technical selling, a stretched short-term RSI at 40.79, and heightened trading interest that traders and analysts should watch for signs of follow-through or short-covering.